CrisPRO Blog

Insights, news, and research at the intersection of AI and oncology.

Part 2: Who is the system failing most, and why?

We built a computational engine and pointed it at 427 real ovarian cancer patients. We asked one question: who is the system failing most, and why?

Read Full Story

April 09, 2026

Part 4: 2,500 Patients Just Told Us The Same Thing

We took two genes — FAP and CXCL10 — and asked a simple question in each cohort: do patients with FAP below their cohort average and CXCL10 above their cohort average live longer than everyone else?

April 09, 2026

Part 3: The Clock We Didn't Know Was Running

Two trials failed last year. Not because the drugs didn't work. Because nobody knew what time it was.

April 09, 2026

Part 1: The Signal We Weren't Looking For: Metformin

You probably know Metformin as a diabetes drug. Costs $7 to $15 a month at any pharmacy. Been around since the 1950s. About as glamorous as a glass of water. But our engine kept ranking it unusually high for ovarian cancer. The IC50 scores were credible. The mechanism was real. And when we dug into the published literature, we found something that genuinely surprised us.